Facebook
Twitter
LinkedIn
Forward
Mark Woodcock gives a broad overview of the multidisciplinary approaches for the treatment of soft tissue sarcomas in adults, and detailed updates in management with systemic therapies. Specific attention is paid to sarcoma sub-types which may warrant special considerations.
|
Valerie W. Collins, PT, CLT-LANA, and Amber Cobia, PT, DPT, CLT, introduce the audience to the anatomy and physiology of the lymphatic system, who is at risk of developing lymphedema, and therapeutic interventions for both mild and severe cases of lymphedema.
|
Megan McElfresh, PA-C, provides an overview of the pathophysiology, diagnosis, prevention, and treatment of graft vs host disease post hematopoietic stem cell transplant.
|
Dr. Benyam Muluneh from the UNC Eshelman School of Pharmacy will discuss relevant topics in cancer pharmacy for North Carolina cancer providers, such as adherence to oral anti-cancer therapies, evolving pharmaceutical practice models (e.g. specialized clinics), toxicity measurement and management, access, and other issues.
|
Cindy Kelly, FNP-BC, ACHPN, and Vineeta Rao, PharmD, BCPS, review opioid and nonopioid treatment options for cancer-related pain. Their presentation addresses patients with cancer and substance use disorder and also cancer patients that are in remission, but who still present with persistent pain.
|
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will go into more detail for treatment options and considerations for treating localized prostate cancer and the management of side effects.
|
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will provide a general overview of Prostate Cancer. The audience will learn about basic pathophysiology and epidemiology as it relates to both local and advanced disease. This course will then provide insight into the pros & cons of prostate cancer screening as well as the accepted diagnostic procedures & scoring.
|
In this course, Mary Dunn, MSN, RN, NP-C, OCN, will discuss the different treatment options for advanced prostate cancer as well as considerations for management side effects and maximizing a survivor’s quality of life.
|
Siddharth Sheth, DO, MPH, will provide a brief overview of clinical factors relevant to head and neck cancers and basic management. Themain focus will be the current use of technologies that aid with the diagnosis, treatment selection, and monitoring of patientswith head and neck cancers. This includes next generation sequencing assays for DNA sequencing, RNA sequencing, andcirculating tumor DNA. The goal of the presentation is for providers to be comfortable with ordering and basic interpretation ofthese tests.
|
Hung-Jui Tan, MD, MSHPM, will review recent practice-changing research and new management recommendations for patients with prostate, kidney, bladder, and testicular cancer.
|